Vectura Group plc appoints James Ward-Lilley as CEO
Vectura Group plc announced the appointment of James Ward-Lilley as CEO and Executive Director. James will succeed Dr Chris Blackwell who, as previously announced, leaves Vectura at the end of June 2015.
James joins the Group on 1 October 2015 from AstraZeneca where he is currently Vice President Respiratory, Inflammation & Autoimmunity, GPPS (“Global Product and Portfolio Strategy”). In his current role James has responsibility for the development of AstraZeneca’s RIA (“Respiratory, Inflammation and Autoimmunity”) strategy which has included the recent acquisitions of Almirall’s respiratory business and Pearl Therapeutics.
Prior to this, James led the AstraZeneca Investor Relations team from 2011 to 2012. James has had an extensive career at AstraZeneca, spanning 28 years across a variety of commercially focused roles. James progressed from sales and marketing roles in the UK through to Country Head of Belgium and Luxembourg a position he held between 2002 and 2005. He then led AstraZeneca's business in China to become the number one pharmaceutical company in the market in 2008. James went on to become Regional Vice President for Central Eastern Europe and the Middle East where the business enjoyed a period of strong growth with sales doubling to $2billion during his tenure.
James is a BA Hons graduate, has an MBA and holds the Institute of Marketing Diploma.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
